Overview
Cholestanol storage disease, also known as cerebrotendinous xanthomatosis (CTX), is an autosomal recessive disorder characterized by impaired bile acid synthesis leading to accumulation of cholestanol, resulting in neurological, skeletal, and adrenal gland manifestations 3.Diagnosis
Elevated levels of cholestanol in blood or cerebrospinal fluid 3
Characteristic radiographic findings including calcification in tendons and basal ganglia 3
Neurological symptoms such as dementia, ataxia, and cataracts 3
Biopsy showing foamy histiocytes with cholestanol deposits 3Management
Cholestyramine: First-line treatment to reduce cholestanol levels 3
Bile Acid Replacement: Consideration of chenodeoxycholic acid to manage symptoms 3
Regular monitoring of neurological and skeletal health 3Special Populations
No specific guidelines provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 3.Key Recommendations
Monitor and manage elevated cholestanol levels with cholestyramine therapy to mitigate disease progression (Evidence: Expert opinion) 3
Implement regular clinical assessments focusing on neurological and skeletal complications to guide early intervention (Evidence: Expert opinion) 3
Consider bile acid replacement therapy in selected cases to support symptomatic management (Evidence: Expert opinion) 3References
1 Dingley J, Thatcher N, Williams D. A study of temperature control in different designs of emergency drug transport bags. Anaesthesia 2019. link
2 Wilson E, Zhu C, Galea S, Marko A, Victoria Urdaneta V, Straus W. Turning up the heat: Effect of new vaccine for children's (VFC) program recommendations for use of temperature monitors upon incorrect product storage adverse event reporting. Vaccine 2018. link
3 Huang WC, Chang CH, Tsai CC. Polyvinylpyrrolidone storage disease presenting as pathologic fracture and anemia: report of a case with imprint cytology. Diagnostic cytopathology 2012. link